Review Article
Chronic Eosinophilic Pneumonia: A Review
Abstract
Chronic eosinophilic pneumonia (CEP) is a disease of unknown cause. The hallmark of CEP is eosinophil accumulation in the lungs. While the triggering factor is unknown, eosinophil accumulation in the lungs is now believed to be secondary to the actions of eosinophil-specific chemoattractants, including eotaxin and regulated upon activation, normal T-cell expressed and secreted (RANTES), and IL-5 released from Th2 lymphocytes in the lungs. There is a female preponderance in CEP, with a peak incidence in the 5th decade; the onset is insidious with weight loss, cough, and dyspnea. An atopic history is common, but asthma is not a prerequisite for the development of CEP. Airways obstruction may develop during the course of CEP, but may also result from CEP. The chest x-ray usually shows bilateral peripheral shadows, which may be migratory. Peripheral eosinophilia is usual. Standard treatment of CEP is with oral steroids, usually with dramatic resolution of symptoms and radiographic changes; however, relapses are common when the daily steroid dose is reduced below 15 mg. Current data suggest that when treatment is stopped, relapse is common in the majority of patients (>80%) followed for a sufficiently long period of time. Some recent reports suggest that treatment with inhaled steroids may be of some value in this condition.
Key Points
* While the precise etiology of chronic eosinophilic pneumonia is unknown, it is now believed that IL-5 may play a pivotal role: an unknown insult/stimulus triggers the accumulation of Th2 cells and release of IL-5 and other chemoattractants from the peripheral circulation into the lungs, which results in eosinophil accumulation in the lungs.
* Pre-existing asthma and atopy are not prerequisites for the development of chronic eosinophilic pneumonia (CEP).
* There are some data to suggest that CEP may itself cause airway obstruction.
* Standard treatment is with oral steroids; anecdotal reports suggest a role for inhaled steroids.
* The majority of patients with CEP will relapse after varying periods of time; sometimes after ten years or more, unless treatment is maintained.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.